The closing price of Puma Biotechnology Inc (NASDAQ: PBYI) was $6.48 for the day, down -1.07% from the previous closing price of $6.55. In other words, the price has decreased by -$0.07 from its previous closing price. On the day, 899697 shares were traded.
Ratios:
Our analysis of PBYI’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.63 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.77. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.86. In the meantime, Its Debt-to-Equity ratio is 2.90 whereas as Long-Term Debt/Eq ratio is at 2.19.
Goldman Downgraded its Neutral to Sell on October 08, 2019, whereas the target price for the stock was revised from $24 to $8.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 03 when AUERBACH ALAN H sold 41,396 shares for $4.49 per share. The transaction valued at 185,698 led to the insider holds 6,936,947 shares of the business.
NOUGUES MAXIMO F sold 15,682 shares of PBYI for $70,348 on Jan 03. The Chief Financial Officer now owns 128,666 shares after completing the transaction at $4.49 per share. On Jan 03, another insider, Ludwig Jeffrey Jerome, who serves as the Chief Commercial Officer of the company, sold 12,956 shares for $4.49 each. As a result, the insider received 58,119 and left with 99,970 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PBYI now has a Market Capitalization of 308.26M and an Enterprise Value of 335.46M. As of this moment, Puma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 88.04, and their Forward P/E ratio for the next fiscal year is 21.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.35 while its Price-to-Book (P/B) ratio in mrq is 7.95. Its current Enterprise Value per Revenue stands at 1.46 whereas that against EBITDA is 11.99.
Stock Price History:
Over the past 52 weeks, PBYI has reached a high of $7.73, while it has fallen to a 52-week low of $2.13. The 50-Day Moving Average of the stock is 5.00, while the 200-Day Moving Average is calculated to be 3.71.
Shares Statistics:
PBYI traded an average of 443.72K shares per day over the past three months and 914.74k shares per day over the past ten days. A total of 41.18M shares are outstanding, with a floating share count of 36.69M. Insiders hold about 22.88% of the company’s shares, while institutions hold 56.01% stake in the company. Shares short for PBYI as of Jan 31, 2024 were 3.21M with a Short Ratio of 7.23, compared to 2.9M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 6.74% and a Short% of Float of 7.92%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of $0.3 for the current quarter, with a high estimate of $0.35 and a low estimate of $0.27, while EPS last year was -$0.12. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0.55 and $0.46 for the fiscal current year, implying an average EPS of $0.49. EPS for the following year is $0.3, with 3 analysts recommending between $0.56 and $0.14.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 2 analysts. It ranges from a high estimate of $74M to a low estimate of $73.1M. As of the current estimate, Puma Biotechnology Inc’s year-ago sales were $65.7M, an estimated increase of 11.90% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $56.5M, an increase of 7.10% less than the figure of $11.90% in the same quarter last year. There is a high estimate of $56.5M for the next quarter, whereas the lowest estimate is $56.5M.
A total of 3 analysts have provided revenue estimates for PBYI’s current fiscal year. The highest revenue estimate was $239M, while the lowest revenue estimate was $236.6M, resulting in an average revenue estimate of $237.7M. In the same quarter a year ago, actual revenue was $228M, up 4.30% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $244.7M in the next fiscal year. The high estimate is $248.4M and the low estimate is $241M. The average revenue growth estimate for next year is up 2.90% from the average revenue estimate for this year.
